Tumor specific t-cell receptors
AssigneeMax-DelbrüCk-Centrum FüR Molekulare Medizin (Mdc) Berlin-Buch
InventorsThomas BLANKENSTEIN, Gerald WILLIMSKY
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for the production of novel T-cell receptors (TCR) which provide a reduced risk of adverse events in immune therapy, specifically in adoptive T cell transfer. The TCRs produced according to the method of the invention are specific for tumor cells and do not react with healthy tissue. Furthermore provided are nucleic acids encoding the TCR of the invention, vectors and host cells comprising the TCRs of the invention as well as their use is the treatment of tumorous diseases.
Claims28
A method for the production of a human T cell receptor (TCR) that is specific for tumorous cells and has reduced adverse effects in adoptive T-cell therapy, wherein said method comprises:
- providing a host organism expressing unrearranged human TCR loci,
- b. immunizing said host organism with a peptide comprising an epitope specific for a tumor specific antigen (TSA),
- isolating from said host organism a T cell clone having an activity against said human-mutated TSA, and
- d. optionally, isolating from said T cell clone the TCR, wherein said TSA is selected out of the class of somatic mutated antigens.
(canceled)
(canceled)
(canceled)
A TCR comprising an alpha and/or beta chain, wherein said alpha and/or beta chain comprises at least one CDR3 domain according to any one of SEQ ID NO:
- 28 to 41.
26-27. (canceled)
29-30. (canceled)
Dependencies are inferred from the claim text.